Sanofi’s AgomAb Therapeutics NV AGMB Stock Holding History

Sanofi’s Portfolio AGMB Stock Details AGMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.1M	Hold	2,783,096	–	–	6.76%	6
2026 Q1	$29.2M	Buy	+2,783,096	New	+$39.4M	8.69%	5

Other funds holding AGMB

EFM

EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Andera Partners Paris $206M AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Sanofi's AGMB Position: Q2 2026 in Review

Sanofi held its AgomAb Therapeutics NV (AGMB) position steady in Q2 2026 at 2,783,096 shares worth $36.1M. The position accounts for 6.76% of the portfolio, ranked #6.

Sanofi first reported a position in AGMB in Q1 2026 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

Sanofi held 2,783,096 shares of AgomAb Therapeutics NV worth $36.1M as of Q2 2026.
Sanofi left its AgomAb Therapeutics NV share count unchanged in Q2 2026.
AgomAb Therapeutics NV made up 6.76% of Sanofi's portfolio in Q2 2026, its #6 holding.
Sanofi first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 2 quarters since.
34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on Sanofi's 13F filing for Q2 2026, filed 28 Jul 2026.